The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT-EHA CAR-T 2019 | CAR T-cell therapy economics in the real world
Duane Schulthess, BA, from Vital Transformation, Flanders, Belgium, discusses the necessity of real-world data for demonstrating the value of CAR T-cell therapy to health technology assessors. Speaking at the 1st European CAR T-Cell Meeting, held in Paris, France, Mr Schulthess reports that to overcome the barriers across both the approval process and reimbursement, it is crucial to prove the real-world safety, efficacy and cost-effectiveness of CAR T-cell therapy. This meeting was co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA).
